Drug or technology

Viral Vaccines

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 9, 2026 · JOURNAL ARTICLE

Dynamic epidemiological changes of hand, foot, and mouth disease and real-world effectiveness of EV-A71 vaccination: A case study in Shanghai (2009-2023).

Human Vaccines & Immunotherapeutics

Rigorous test-negative design study with large real-world population (73,160 cases) over 15 years demonstrating vaccine effectiveness against the target pathogen with precise confidence intervals; not practice-changing because vaccination policy was already implemented.

Strong EvidenceVaccine Efficacy Xin Liu Mei Zeng

Reported

Primary endpoint: VE two-dose aga…89.9%

95% CI for two-dose VE74.5-96.0

VE one-dose against EV-A71-associ…67.9%

AUG 4, 2026 · JOURNAL ARTICLE

Advancing human metapneumovirus vaccine development through fusion protein stabilization.

Virology

This is a narrative review synthesizing structure-guided protein engineering strategies and preclinical immunogenicity data, raising mechanistic questions about pre-F stabilization rather than reporting a definitive clinical or confirmatory experimental result.

Hypothesis-GeneratingVaccine Development Antibodies, Neutralizing Viral Vaccines

Study details

DesignNarrative review